Note: as of April 2019, the manufacturer has decided to discontinue the product after the confirmatory RCT was negative.
Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it was used
Patient drug information
- Brief patient counseling information can be found in the Olaratumab (Lartruvo) package insert 
History of changes in FDA indication
Soft tissue sarcoma - WITHDRAWN
- 2016-10-19: Accelerated approval for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate. (Based on CP15-0806)
- 2020-02-25: Approval withdrawn. (Based on ANNOUNCE)
History of changes in EMA indication
- 2016-11-09: Initial authorization
- 2019-04-26: Approval withdrawn. (Based on ANNOUNCE)
History of changes in Health Canada indication
- 2017-11-23: Initial notice of compliance with conditions
- 2020-10-08: Approval withdrawn.
Also known as
- Code names: LY3012207, IMC-3G3
- Brand name: Lartruvo